Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shenzhen Sanjiu Traditional Chinese Medicine Investment & Development is a subsidiary of China Resources Sanjiu Medical & Pharmaceutical, specializing in the investment and industrialization of Traditional Chinese Medicine (TCM). The company focuses on the entire TCM value chain, including the cultivation of medicinal herbs, the development of standardized processing techniques, and the production of TCM formula granules. It plays a vital role in the parent company's strategy to modernize TCM through scientific research and quality control. The company's products support the well-known 999 brand, which is a leader in the Chinese consumer healthcare market for respiratory and digestive ailments.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shenzhen 999 Chinese Medicine Investment & Development.